Vitabiotics Turkey has announced that it has joined the Prisum Healthcare family, an international health company with a leading presence in Romania, Greece, and Bulgaria. The integration marks a strategic transition for the Turkish operations of Vitabiotics, the UK-based manufacturer of Perfectil, Pregnacare, Wellwoman, Wellman, Osteocare, and other well-known vitamin and mineral supplement brands.

The announcement was published on April 2, 2026, on the Vitabiotics Turkey website. No financial terms were disclosed.

Vitabiotics has operated in Turkey for nearly a decade, during which the company recorded strong growth in the country's rapidly expanding dietary supplement market. The Turkish market for food supplements has been among the fastest-growing in Europe, driven by rising health awareness and expanding pharmacy and retail distribution networks.

Vitabiotics Turkey's commercial portfolio includes Perfectil, Osteocare, Wellwoman, Wellman, Wellteen, Wellkid, Pregnacare, Feroglobin, Neurozan, Menopace, Jointace, Visionace, Immunace, and the Ultra vitamin range.

Prisum Healthcare is an international health company focused on nutritional products and plasma-based therapies, with operations across multiple European markets. The company brings more than 30 years of international experience and an established distribution infrastructure in Central and Southeastern Europe.

Following the integration, Vitabiotics Turkey aims to leverage Prisum Healthcare's regional expertise to expand product accessibility, develop new B2B channel opportunities, and strengthen its pharmacy distribution network in Turkey.

The transaction represents a transfer of the Turkish operations of a UK-headquartered consumer health brand to a Central and Southeastern European healthcare group. For market participants, the integration illustrates the continued consolidation of the European over-the-counter and dietary supplement sector, with regional operators acquiring established brand presences in high-growth emerging markets.

From a Turkish market perspective, the transaction does not affect the continuity of Vitabiotics products in Turkish pharmacies. The company has confirmed that its product range and commercial activities will continue under Prisum Healthcare's ownership, with a stated objective of increasing product accessibility and creating new business opportunities.

This summary is based on publicly available information as of April 2, 2026. It is provided for informational purposes only and does not constitute legal advice.